{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T21:10:52Z","timestamp":1761858652142,"version":"build-2065373602"},"reference-count":37,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","pathologyjournal.rcpa.edu.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.pathol.2021.12.290","type":"journal-article","created":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T16:43:23Z","timestamp":1646325803000},"page":"526-532","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pathologist initiated reflex BRAF mutation testing in metastatic melanoma: experience at a specialist melanoma treatment centre"],"prefix":"10.1016","volume":"54","author":[{"given":"Alison J.","family":"Potter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J.","family":"Colebatch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert V.","family":"Rawson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter M.","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy A.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruta","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"O'Toole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robyn P.M.","family":"Saw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sydney","family":"Ch'ng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander M.","family":"Menzies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgina V.","family":"Long","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard A.","family":"Scolyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pathol.2021.12.290_bib1","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1200\/JCO.2010.32.4327","article-title":"Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma","volume":"29","author":"Long","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2021.12.290_bib2","doi-asserted-by":"crossref","first-page":"3826","DOI":"10.1002\/cncr.29586","article-title":"Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors","volume":"121","author":"Menzies","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.pathol.2021.12.290_bib3","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.pathol.2015.12.008","article-title":"The molecular profile of metastatic melanoma in Australia","volume":"48","author":"Lyle","year":"2016","journal-title":"Pathology"},{"key":"10.1016\/j.pathol.2021.12.290_bib4","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1177\/1758834015616934","article-title":"Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy","volume":"8","author":"Eroglu","year":"2016","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.pathol.2021.12.290_bib5","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2021.12.290_bib6","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1158\/1078-0432.CCR-11-2479","article-title":"Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma","volume":"18","author":"Wilmott","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pathol.2021.12.290_bib7","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1158\/1078-0432.CCR-18-1680","article-title":"Distinct molecular profiles and immunotherapy treatment outcomes of V600E and V600K BRAF-mutant melanoma","volume":"25","author":"Pires da Silva","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pathol.2021.12.290_bib8","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.3390\/cancers13092282","article-title":"Defining the criteria for reflex testing for BRAF mutations in cutaneous melanoma patients","volume":"13","author":"Zhou","year":"2021","journal-title":"Cancers (Basel)"},{"author":"Australian Government Department of Health","key":"10.1016\/j.pathol.2021.12.290_bib9"},{"key":"10.1016\/j.pathol.2021.12.290_bib10","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/modpathol.2017.104","article-title":"Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine","volume":"31","author":"Cheng","year":"2018","journal-title":"Mod Pathol"},{"key":"10.1016\/j.pathol.2021.12.290_bib11","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/PAS.0b013e31826485c0","article-title":"Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma","volume":"37","author":"Long","year":"2013","journal-title":"Am J Surg Pathol"},{"author":"Australian Government Department of Health","key":"10.1016\/j.pathol.2021.12.290_bib12"},{"key":"10.1016\/j.pathol.2021.12.290_bib13","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/PAS.0000000000000136","article-title":"Intrapatient homogeneity of BRAFV600E expression in melanoma","volume":"38","author":"Menzies","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.pathol.2021.12.290_bib14","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1158\/1078-0432.CCR-12-0052","article-title":"Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma","volume":"18","author":"Menzies","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pathol.2021.12.290_bib15","first-page":"472","article-title":"Melanoma staging: evidence-based changes in the American Joint committee on cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J Clin"},{"year":"2019","series-title":"BRAF Testing for Dabrafenib\/Trametinib in Stage III Melanoma","key":"10.1016\/j.pathol.2021.12.290_bib16"},{"year":"2020","series-title":"Medicare Benefits Schedule Book","author":"Australian Government Department of Health","key":"10.1016\/j.pathol.2021.12.290_bib17"},{"year":"2014","series-title":"Primary Cutaneous Melanoma Structured Reporting Protocol, 2nd Edition","author":"Scolyer","key":"10.1016\/j.pathol.2021.12.290_bib18"},{"year":"2019","series-title":"Invasive Melanoma, Histopathology Reporting Guide, 2nd Edition","author":"Scolyer","key":"10.1016\/j.pathol.2021.12.290_bib19"},{"key":"10.1016\/j.pathol.2021.12.290_bib20","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/his.12992","article-title":"BRAF(V600E) and NRAS(Q61L\/Q61R) mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting","volume":"69","author":"Kakavand","year":"2016","journal-title":"Histopathology"},{"key":"10.1016\/j.pathol.2021.12.290_bib21","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/PAT.0000000000000077","article-title":"Concordant BRAFV600E mutation status in primary melanomas and associated naevi: implications for mutation testing of primary melanomas","volume":"46","author":"Kakavand","year":"2014","journal-title":"Pathology"},{"key":"10.1016\/j.pathol.2021.12.290_bib22","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/cup.13393","article-title":"High concordance of BRAF mutational status in matched primary and metastatic melanoma","volume":"46","author":"Cormican","year":"2019","journal-title":"J\u00a0Cutan Pathol"},{"key":"10.1016\/j.pathol.2021.12.290_bib23","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1038\/bjc.2013.796","article-title":"Intra-patient heterogeneity of BRAF mutation status: fact or fiction?","volume":"111","author":"Menzies","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.pathol.2021.12.290_bib24","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1002\/cncr.27693","article-title":"Number of primary melanomas is an independent predictor of survival in patients with metastatic melanoma","volume":"118","author":"Murali","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.pathol.2021.12.290_bib25","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1001\/archdermatol.2010.2","article-title":"Increased risk of second primary cancers after a diagnosis of melanoma","volume":"146","author":"Bradford","year":"2010","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.pathol.2021.12.290_bib26","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s00428-016-1935-8","article-title":"The effects of implementing synoptic pathology reporting in cancer diagnosis: a systematic review","volume":"468","author":"Sluijter","year":"2016","journal-title":"Virchows Arch"},{"key":"10.1016\/j.pathol.2021.12.290_bib27","doi-asserted-by":"crossref","first-page":"587","DOI":"10.5858\/arpa.2014-0082-RA","article-title":"Cancer biomarkers: the role of structured data reporting","volume":"139","author":"Simpson","year":"2015","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.pathol.2021.12.290_bib28","doi-asserted-by":"crossref","first-page":"48","DOI":"10.4103\/2153-3539.194840","article-title":"Reflex test reminders in required cancer synoptic templates decrease order entry error: an analysis of mismatch repair immunohistochemical orders to screen for Lynch syndrome","volume":"7","author":"Kilgore","year":"2016","journal-title":"J\u00a0Pathol Inform"},{"key":"10.1016\/j.pathol.2021.12.290_bib29","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/PAS.0b013e31829d7f35","article-title":"Data set for pathology reporting of cutaneous invasive melanoma: recommendations from the international collaboration on cancer reporting (ICCR)","volume":"37","author":"Scolyer","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.pathol.2021.12.290_bib30","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.2217\/fon-2019-0666","article-title":"KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma","volume":"16","author":"Luke","year":"2020","journal-title":"Future Oncol"},{"year":"2021","series-title":"Merck\u2019s KEYTRUDA\u00ae (pembrolizumab) significantly prolonged recurrence-free survival (RFS) compared to placebo as adjuvant therapy for patients with stage II resected high-risk melanoma in Phase 3 KEYNOTE-716 Trial","key":"10.1016\/j.pathol.2021.12.290_bib31"},{"key":"10.1016\/j.pathol.2021.12.290_bib32","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/cncr.32585","article-title":"Considering adjuvant therapy for stage II melanoma","volume":"126","author":"Poklepovic","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.pathol.2021.12.290_bib33","doi-asserted-by":"crossref","first-page":"286","DOI":"10.21037\/tlcr.2019.04.14","article-title":"Molecular testing strategies in non-small cell lung cancer: optimizing the diagnostic journey","volume":"8","author":"Gregg","year":"2019","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.pathol.2021.12.290_bib34","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1093\/annonc\/mdv208","article-title":"Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer","volume":"26","author":"Lim","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.pathol.2021.12.290_bib35","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.1200\/JOP.2016.014019","article-title":"Impact of reflex EGFR\/ALK testing on time to treatment of patients with advanced nonsquamous non-small-cell lung cancer","volume":"13","author":"Cheema","year":"2017","journal-title":"J\u00a0Oncol Pract"},{"key":"10.1016\/j.pathol.2021.12.290_bib36","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3747\/co.24.3266","article-title":"Rate of EGFR mutation testing for patients with nonsquamous non-small-cell lung cancer with implementation of reflex testing by pathologists","volume":"24","author":"Cheema","year":"2017","journal-title":"Curr Oncol"},{"key":"10.1016\/j.pathol.2021.12.290_bib37","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.pathol.2021.11.002","article-title":"BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting","volume":"54","author":"Scolyer","year":"2022","journal-title":"Pathology"}],"container-title":["Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302522000629?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031302522000629?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T16:29:00Z","timestamp":1758472140000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031302522000629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S0031302522000629"],"URL":"https:\/\/doi.org\/10.1016\/j.pathol.2021.12.290","relation":{},"ISSN":["0031-3025"],"issn-type":[{"type":"print","value":"0031-3025"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pathologist initiated reflex BRAF mutation testing in metastatic melanoma: experience at a specialist melanoma treatment centre","name":"articletitle","label":"Article Title"},{"value":"Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pathol.2021.12.290","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}